JOHN JOHNSON - 04 Jun 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Director
Signature: /s/ Beth Hecht, Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 04 Jun 2025
Net transactions value: $0
Form type: 4
Filing time: 04 Jun 2025, 19:01:31 UTC
Previous filing: 27 May 2025
Next filing: 11 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
JOHNSON JOHN	Director	C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO	/s/ Beth Hecht, Attorney-in-Fact	04 Jun 2025	0001410781

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+50,000	+5.6%	$0.000000	940,983	04 Jun 2025	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 4, 2026 or the date of the Company's next annual meeting of stockholders.